Description

RO27-3225 TFA is potent and selective melanocortin 4 receptor (MC4R) agonist with an EC50 of 1 nM and 8 nM for MC4R and MC1R, respectively. RO27-3225 TFA shows ~30-fold selectivity for MC4R over MC3R. RO27-3225 TFA has neuroprotective and anti-inflammatory effects[1][2][3].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)–COVID-19-immunoregulation–C41H53F3N12O8—-[1]Giuliani D, et al. Selective melanocortin MC4 receptor agonists reverse haemorrhagic shock and prevent multiple organ damage. Br J Pharmacol. 2007 Mar;150(5):595-603.|[2]Zhang Y, et al. Effects of RO27-3225 on neurogenesis, PDGFRβ+ cells and neuroinflammation after cerebral infarction. Int Immunopharmacol. 2020 Feb 11;81:106281.|[3]Benoit SC, et al. A novel selective melanocortin-4 receptor agonist reduces food intake in rats and mice without producing aversive consequences. J Neurosci. 2000 May 1;20(9):3442-8.—-898.93–98.94–CCCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N(CC(N)=O)C)=O)CC1=CNC2=C1C=CC=C2)=O)CCCNC(N)=N)=O)CC3=CC=CC=C3)=O)CC4=CN=CN4)=O.O=C(O)C(F)(F)F–Inflammation/Immunology; Neurological Disease–DMSO : 100 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)–Melanocortin Receptor–MC4R–GPCR/G Protein;Neuronal Signaling–Peptides